Key result
Higher NT-proBNP linked to ~137% increased incident CKD risk in type 2 diabetes.
Why the study?
The association between serum NT-proBNP level and incident chronic kidney disease in patients with type 2 diabetes was not well known.
Does higher serum NT-proBNP level predict incident chronic kidney disease in patients with type 2 diabetes?
Cohort (n=211)
Does higher serum NT-proBNP level predict incident chronic kidney disease in patients with type 2 diabetes?
Hazard Ratio: 2.37 (95% CI 1.09–5.48)
p-value: p=0.028
Higher serum NT-proBNP levels independently predict the development of chronic kidney disease in patients with type 2 diabetes.
May inform CKD risk stratification in type 2 diabetes; leaves open whether NT-proBNP adds value beyond standard predictors.
BACKGROUND AND OBJECTIVE: Previous studies revealed the association between serum Nterminal pro-brain natriuretic peptide (NT-proBNP) level and chronic kidney diseases (CKD) in general population. However, little is known about the association between serum NT-proBNP level and incident CKD in patients with type 2 diabetes. Thus, we investigated the impact of serum NT-proBNP level on incident CKD in patients with type 2 diabetes. METHOD: We enrolled 211 type 2 diabetic patients without CKD in this cohort study. CKD was diagnosed as estimated glomerular filtration rate <60 ml/min/1.73 m2. We divided the patients into three groups according to the tertiles of serum NT-proBNP level. Univariates and multivariate hazard ratios (HRs) for the incident CKD were calculated by Cox regression analyses. RESULTS: Over the median follow-up period of 7 years, 56 patients developed incident CKD. Log NTproBNP was positively associated with incident CKD (HR 3.70, 95%CI 1.72-8.18, p <0.001). Compared with the lowest level of serum NT-proBNP tertile (≤36 pg/mL), the highest level of serum NTproBNP tertile (≥84 pg/mL) showed increased risk of incident CKD after adjusting age, sex, body mass index, hemoglobin A1c, creatinine, smoking, usage of hypertension drug and urinary albumin excretion at baseline examination (adjusted HR2.37, 95% CI 1.09-5.48, p = 0.028). CONCLUSION: Serum NT-proBNP level is an independent biomarker for incident CKD in patients with type 2 diabetes.
No takes yet. Share an insight, caveat, or question.
Sawada et al. (2018) conducted a cohort in Type 2 diabetes without chronic kidney disease (n=211). Highest tertile of serum NT-proBNP (≥84 pg/mL) vs. Lowest tertile of serum NT-proBNP (≤36 pg/mL) was evaluated on Incident chronic kidney disease (eGFR <60 ml/min/1.73 m2) (adjusted HR 2.37, 95% CI 1.09-5.48, p=0.028). Higher serum NT-proBNP levels (≥84 vs ≤36 pg/mL) were associated with an increased risk of incident CKD in patients with type 2 diabetes (adjusted HR 2.37; 95% CI 1.09-5.48; p=0.028).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: